Effect of triptolide in combination with Dox, gemtuzumab ozogamicin, or Ara-C on cell death in AML cells. OCI-AML3 cells (0.2 × 106/mL) were treated with low concentrations of triptolide, Dox, gemtuzumab ozogamicin, Ara-C, or their combinations, as indicated, for 48 hours. (A) XIAP and Mcl-1 protein levels in OCI-AML3 cells treated with low concentrations of triptolide at 48 hours. (B) Cell viability determined by annexin V staining in OCI-AML3 cells treated with triptolide, Dox, gemtuzumab ozogamicin, Ara-C, or the combinations for 48 hours. (C) Cell cycle distribution of OCI-AML3 cells treated with triptolide, Dox, gemtuzumab ozogamicin, Ara-C, or their combinations at 48 hours, as shown by PI staining. (D) Blasts (1 × 106/mL) from patients with AML (n = 4) were treated with low concentrations of triptolide, Dox, gemtuzumab ozogamicin, or their combinations for 48 hours. Cell viability was determined by annexin V staining.
